Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to -$71,000.

  • Xeris Biopharma Holdings' Cash from Investing Activities fell 100.72% to -$71,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 0.84%. This contributed to the annual value of $4.9 million for FY2024, which is 181.33% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Cash from Investing Activities stood at -$71,000, which was up 74.55% from -$279,000 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Cash from Investing Activities registered a high of $36.6 million during Q4 2021, and its lowest value of -$44.0 million during Q1 2023.
  • Moreover, its 3-year median value for Cash from Investing Activities was $4.6 million (2024), whereas its average is -$134,909.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Cash from Investing Activities soared by 404.92% in 2021, and later tumbled by 754.84% in 2023.
  • Xeris Biopharma Holdings' Cash from Investing Activities (Quarterly) stood at $36.6 million in 2021, then plummeted by 74.95% to $9.2 million in 2022, then soared by 62.17% to $14.9 million in 2023, then tumbled by 32.63% to $10.0 million in 2024, then plummeted by 100.72% to -$71,000 in 2025.
  • Its last three reported values are -$71,000 in Q3 2025, -$279,000 for Q2 2025, and -$13,000 during Q1 2025.